Press release ·
Keyline and Aldermoor start a partnership in autoimmune disease
Keyline will design binders for one target chosen by Aldermoor.
CAMBRIDGE, Mass., Feb. 10, 2026 · Keyline Bio and Aldermoor today signed a partnership to design binders for one autoimmune disease target that Aldermoor chose. Keyline gets an upfront payment and can earn development milestones and royalties. Aldermoor leads development and any clinical studies.
Forward-looking statements. This press release has forward-looking statements, such as plans for clinical studies, timing and the use of funds. They are based on what Keyline knows today and are subject to risks and uncertainties, so actual results can be different. Keyline does not have to update them. (Sample text for a demo site.)